Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

NCT06964113 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.

NCT NCT06964113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06964113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
Lead sponsor
Eisai Korea Inc.
Phase
Phase 4
Overall status
Active, not recruiting
Start date
June 11, 2025
Completion date
November 30, 2027
Enrollment
94 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis